Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aji Bio-Pharma Expands Small Molecule Mfg. Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aji Bio-Pharma Expands Small Molecule Mfg. Capabilities

To add a new 8,500 square meter production facility in Visakhapatnam, India.

By: Contract Pharma

Contract Pharma Staff

Ajinomoto Bio-Pharma Services is significantly expanding its small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India. Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed mid-2022.

The facility doubles the production capacity at the site to 310 m3 for active pharmaceutical ingredients (API) and intermediates and has dedicated equipment to manage OEB 4 high potency ingredients. The site has also completed renovations on existing lab space to support additional R&D activities. It’s estimated that the expansion will create at least 60 new jobs at the site.

The U.S. FDA approved Ajinomoto Bio-Pharma Services India manufacturing site, which was designed, constructed and is managed based on the Aji Bio-Pharma Belgian sites’ GMP operating standards and quality systems.

“We are very excited to be investing in this additional production capacity to continue delivering high quality, cost-effective small molecule manufacturing services for our customers,” said K.V.V. Raju, Head of Site Operations and CEO, Ajinomoto Bio-Pharma India Pvt. Ltd.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics